OBJECTIVE: Our aims were to evaluate the effects of polymorphisms in the hepatic drug uptake transporter organic anion transporting polypeptide 1B1 (OATP1B1, SLCO1B1) and efflux transporters multidrug resistance-associated protein 2 (MRP2, ABCC2), bile salt export pump (BSEP, ABCB11), and breast cancer-related protein (BCRP, ABCG2) on single-dose pravastatin pharmacokinetics in healthy European- and African-American participants. METHODS: The pharmacokinetics of a single oral 40 mg dose of pravastatin was determined in 107 participants (69 European-Americans and 38 African-Americans). Participants were genotyped for known OATP1B1, MRP2, BSEP, and BCRP polymorphisms. Baseline serum total and unconjugated plasma bilirubin concentrations were also determined. RESULTS: OATP1B1 genotypes were ethnicity-dependent with a 521C allele frequency of approximately 15% in European-Americans and approximately 1% in African-Americans. SLCO1B1 521TC genotype was associated with significantly higher pravastatin area under the curve [AUC(0-5)] (P=0.01) and Cmax values (P<0.05). When analyzed by diplotype, SLCO1B1*1a/*15 (N=8) participants exhibited 45 and 80% higher AUC values than SLCO1B1*1a/*1a (N=29) (P=0.013) and SLCO1B1*1b/*1b (N=34) (P=0.001) carriers, respectively. SLCO1B1*15/*15 (N=2) participants exhibited 92 and 149% higher AUC values than SLCO1B1*1a/*1a (P=0.017) and SLCO1B1*1b/*1b (P=0.011) carriers, respectively. European-Americans had significantly higher plasma pravastatin AUC(0-5) (P=0.01) and Cmax values (P=0.009) than African-Americans. Neither ABCC2, ABCB11, nor ABCG2 genotypes were associated with differences in pravastatin pharmacokinetics. We did not observe an effect of SLCO1B1 genotype on baseline total or unconjugated bilirubin levels. CONCLUSION: SLCO1B1 genotype, in particular the 521C allele, had a significant effect on the pharmacokinetics of pravastatin. Even when adjusted for the presence of the SLCO1B1 521C or 388G variant allele, European-Americans demonstrated significantly higher pravastatin AUC and Cmax values than African-Americans.
OBJECTIVE: Our aims were to evaluate the effects of polymorphisms in the hepatic drug uptake transporter organic anion transporting polypeptide 1B1 (OATP1B1, SLCO1B1) and efflux transporters multidrug resistance-associated protein 2 (MRP2, ABCC2), bile salt export pump (BSEP, ABCB11), and breast cancer-related protein (BCRP, ABCG2) on single-dose pravastatin pharmacokinetics in healthy European- and African-American participants. METHODS: The pharmacokinetics of a single oral 40 mg dose of pravastatin was determined in 107 participants (69 European-Americans and 38 African-Americans). Participants were genotyped for known OATP1B1, MRP2, BSEP, and BCRP polymorphisms. Baseline serum total and unconjugated plasma bilirubin concentrations were also determined. RESULTS:OATP1B1 genotypes were ethnicity-dependent with a 521C allele frequency of approximately 15% in European-Americans and approximately 1% in African-Americans. SLCO1B1 521TC genotype was associated with significantly higher pravastatin area under the curve [AUC(0-5)] (P=0.01) and Cmax values (P<0.05). When analyzed by diplotype, SLCO1B1*1a/*15 (N=8) participants exhibited 45 and 80% higher AUC values than SLCO1B1*1a/*1a (N=29) (P=0.013) and SLCO1B1*1b/*1b (N=34) (P=0.001) carriers, respectively. SLCO1B1*15/*15 (N=2) participants exhibited 92 and 149% higher AUC values than SLCO1B1*1a/*1a (P=0.017) and SLCO1B1*1b/*1b (P=0.011) carriers, respectively. European-Americans had significantly higher plasma pravastatin AUC(0-5) (P=0.01) and Cmax values (P=0.009) than African-Americans. Neither ABCC2, ABCB11, nor ABCG2 genotypes were associated with differences in pravastatin pharmacokinetics. We did not observe an effect of SLCO1B1 genotype on baseline total or unconjugated bilirubin levels. CONCLUSION:SLCO1B1 genotype, in particular the 521C allele, had a significant effect on the pharmacokinetics of pravastatin. Even when adjusted for the presence of the SLCO1B1 521C or 388G variant allele, European-Americans demonstrated significantly higher pravastatin AUC and Cmax values than African-Americans.
Authors: Kuniaki Morisaki; Robert W Robey; Csilla Ozvegy-Laczka; Yasumasa Honjo; Orsolya Polgar; Kenneth Steadman; Balázs Sarkadi; Susan E Bates Journal: Cancer Chemother Pharmacol Date: 2005-04-19 Impact factor: 3.333
Authors: Kari T Kivistö; Olaf Grisk; Ute Hofmann; Konrad Meissner; Klaus-Uwe Möritz; Christoph Ritter; Katja A Arnold; Dieter Lutjöohann; Klaus von Bergmann; Ingrid Klöting; Michel Eichelbaum; Heyo K Kroemer Journal: Drug Metab Dispos Date: 2005-08-17 Impact factor: 3.922
Authors: Ute I Schwarz; Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Atsuko Suzuki; Brenda F Leake; Younes Mokrab; Kenji Mizuguchi; Richard H Ho; Richard B Kim Journal: Pharmacogenet Genomics Date: 2011-03 Impact factor: 2.089
Authors: Richard H Ho; Brenda F Leake; Dawn M Kilkenny; Henriette E Meyer Zu Schwabedissen; Hartmut Glaeser; Deanna L Kroetz; Richard B Kim Journal: Pharmacogenet Genomics Date: 2010-01 Impact factor: 2.089
Authors: Lisa R Treviño; Noriko Shimasaki; Wenjian Yang; John C Panetta; Cheng Cheng; Deqing Pei; Diana Chan; Alex Sparreboom; Kathleen M Giacomini; Ching-Hon Pui; William E Evans; Mary V Relling Journal: J Clin Oncol Date: 2009-11-09 Impact factor: 44.544
Authors: Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg Journal: Mol Biotechnol Date: 2010-02 Impact factor: 2.695
Authors: Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen Journal: Pharmacogenet Genomics Date: 2010-02 Impact factor: 2.089